Idelalisib for Treatment of Follicular Lymphoma
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Idelalisib for Treatment of Follicular Lymphoma

Sponsor: Gilead Sciences

This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) and evaluate the overall safety profile of idelalisib and the overall response rate (ORR) by Week 24.